RESEARCH
All products are supplied strictly for laboratory and research use only — not for human or veterinary use. By entering, you confirm you are 18 or older and agree to our Terms & Conditions.
Under 18? Leave this siteLaboratory research comparison
A neutral comparison of two distinct synthetic GHRH analogues by research classification, structure and growth-hormone-axis research context.
CJC-1295 without DAC, often described in research catalogues as modified GRF (1-29), is a synthetic 29-residue analogue based on the active N-terminal portion of growth-hormone-releasing hormone. “Without DAC” distinguishes it from material bearing a drug-affinity-complex modification.
Tesamorelin is a synthetic analogue based on the 44-residue human growth-hormone-releasing-hormone sequence, with a trans-3-hexenoic-acid modification at its N-terminus. It is a distinct defined peptide rather than another name for CJC-1295 without DAC.
Both compounds are classified as synthetic GHRH analogues and may be examined in laboratory research concerning GHRH-receptor signalling and the growth-hormone axis. This shared classification is research context, not evidence that their structures, test results or experimental conditions are equivalent.
Their similarity lies in their relationship to GHRH-based research. Their peptide lengths, sequence basis and defining modifications differ, so each should be identified by its own compound name and evaluated against its own analytical documentation.
A shared research category does not make two compounds interchangeable. Researchers should distinguish their molecular identities, study materials, batch numbers, analytical reports and experimental designs, without transferring a result or conclusion from one compound to the other.
Educational laboratory-research information only. This comparison does not provide medical, therapeutic, dosing, administration or human-use guidance.
Your cart is empty.